A splice variant of androgen receptor (AR), AR-V7, lacks in androgen-binding portion and leads to aggressive cancer characteristics. Reverse transcription-polymerase chain reactions (PCRs) and subsequent nested PCRs for the amplification of AR-V7 and prostate-specific antigen (PSA) transcripts were done for whole blood of patients with prostate cancer and male controls.
With primary reverse transcription PCRs, AR-V7 and PSA were detected in 4. 5% and 4. 7% of prostate cancer, respectively. With nested PCRs, AR-V7 messenger RNA (mRNA) was positive in 43. 8% of castration-sensitive prostate cancer and 48. 1% of castration-resistant prostate cancer (CRPC), while PSA mRNA was positive in 6. 3% of castration-sensitive prostate cancer and 18. 5% of CRPC. Whole-blood samples of controls showed AR-V7 mRNA expression by nested PCR. Based on multivariate analysis, expression of AR-V7 mRNA in whole blood was not significantly correlated with clinical parameters and PSA mRNA in blood, while univariate analysis showed a correlation between AR-V7 mRNA and metastasis at initial diagnosis. Detection of AR-V7 mRNA did not predict the reduction of serum PSA in patients with CRPC following abiraterone and enzalutamide administration. In conclusion, AR-V7 mRNA expression in normal hematopoietic cells may have annihilated the manifestation of aggressiveness of prostate cancer and the prediction of the effectiveness of abiraterone and enzalutamide by the assessment of AR-V7 mRNA in blood.
Research and reports in urology. 2016 Jan 28*** epublish ***
Takumi Takeuchi, Yumiko Okuno, Mami Hattori-Kato, Masayoshi Zaitsu, Koji Mikami
Department of Urology, Kanto Rosai Hospital, Kawasaki, Japan. , Department of Urology, Kanto Rosai Hospital, Kawasaki, Japan. Department of Urology, Kanto Rosai Hospital, Kawasaki, Japan. Department of Urology, Kanto Rosai Hospital, Kawasaki, Japan. , Department of Urology, Kanto Rosai Hospital, Kawasaki, Japan.